Navigation Links
Kidney-disease drug with Dartmouth origins licensed in Asia
Date:1/14/2010

Thanks in part to more than a decade of preclinical work by Dartmouth researchers, a Japanese biopharmaceutical firm is preparing to develop and market throughout Asia a drug for the treatment of chronic kidney disease (CKD).

In a deal worth $272 million plus royalties, the firm Kyowa Hakko Kirin bought exclusive rights to the compound bardoxolone methylor CDDO-methyl ester (CDDO-Me), in the scientific literaturefrom Texas-based Reata Pharmaceuticals on Thursday, January 7.

The drug belongs to a family of anti-inflammatory compounds called triterpenoids, which chemist Tadashi Honda, Ph.D., began synthesizing at the Dartmouth laboratory of Gordon Gribble, Ph.D., in 1995. Since then, Dartmouth Medical School pharmacologist Michael B. Sporn, M.D., and his lab team have been testing them for bioactivity.

Sporn and members of his lab, including co-investigator Karen Liby, Ph.D., found in animal trials that synthetic triterpenoids simultaneously inhibit many kinds of tumor cells, suppress inflammation, and protect healthy, non-cancerous cells. While focusing on cancer prevention and treatment, the researchers found that the anti-inflammatory, anti-oxidant and cyto-protective properties of triterpenoids also can apply to a wide range of inflammation-related diseases. These conditions include diseases of the kidney, the heart, the respiratory system, and the central-nervous system.

Triterpenoids "are not anti-oxidants themselves," explains Sporn, DMS's Oscar M. Cohn '34 Professor of Pharmacology and of Medicine. "They turn on the body's own anti-oxidant defenses, which is most important."

Following up on the Sporn lab's cancer research, collaborators at Cornell reported that in tests on rodents, one of the triterpenoids appears to help in preventing such neurodegenerative diseases as Parkinson's, Alzheimer's and Huntington's.

After securing patent protection for the CDDO-Me compounds, Dartmouth College's Technology Transfer Office (TTO) identified Reata as a private-sector collaborator for further development. Under a licensing agreement with Dartmouth, Reata has been conducting human trials with the compounds.

In announcing the deal with Kyowa, Reata reported that "in two Phase 2 trials, bardoxolone significantly improved renal function in Type-2 diabetic patients with advanced CKD. ... Significant improvements were also seen in other markers of renal function, [control of blood-sugar levels], and cardiovascular disease."

The agreement gives Kyowa exclusive rights to develop and sell bardoxolone for CKD and related conditions in Japan, China, Taiwan, Korea and southeast Asia. Reata retains the rights to develop and sell the drug in the United States, Europe, Latin America, and Asian markets beyond Kyowa's territory.

According to Alla Kan, TTO director, the Reata/Kyowa agreement "provides a wonderful opportunity for Dartmouth to bring the fruits of our research to patients. This is a most exciting development and a vivid illustration of academic research transfer to industry for the benefit of humanity."

Sporn, considered "the father of chemoprevention" for his pioneering use of medications to fend off cancer and other diseases, hails the agreement as the culmination of a new drug going " 'all the way' at Dartmouth, from conception, to synthesis, to preclinical development, and then to final licensing to a pharmaceutical company for clinical development."

Sporn also praises the work of his collaborators, particularly Liby and her experiments with mice.

"This woman has a unique talent for doing research," Sporn says.


'/>"/>

Contact: David Corriveau
dms.communications@dartmouth.edu
603-650-0771
Dartmouth College
Source:Eurekalert

Related medicine news :

1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. Rural patients colon and lung cancers diagnosed earlier, Dartmouth research says
3. Chronically Ill Patients Get More Care, Less Quality, Says Latest Dartmouth Atlas
4. Dartmouth-Hitchcock Medical Center Evaluation Findings Demonstrate Masimo Patient SafetyNet(TM) Delivers Improvements in Clinical Outcomes and Patient Safety on General Care Floors
5. Dartmouth research reveals passive learning imprints on the brain just like active learning
6. Dartmouth researchers say too many children see extreme violence in movies
7. Clinicians at Dartmouth-Hitchcock Medical Center Present New Data Showing Masimo Rainbow SET(R) Oximetry and Patient SafetyNet(TM) Improves Patient Outcomes and Reduces the Cost of Care
8. Taming Wide Variations in Spending Key to Health Reform - New England Journal of Medicine Commentary from Dartmouth Atlas Project
9. Dr. Jim Yong Kim Appointed 17th President of Dartmouth College
10. Dartmouth-Hitchcock Medical Center Selects MedAptus for Charge Capture Deployment
11. Dartmouth gets $3 million from the National Science Foundation for IT research in health care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
Breaking Medicine Technology: